These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30443683)

  • 1. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
    Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
    Rizzardo S; Lanzafame M; Lattuada E; Bragantini D; Nicolè S; Calza L; Tacconelli E
    Int J STD AIDS; 2019 Apr; 30(5):467-471. PubMed ID: 30999834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
    Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
    PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
    Suzuki A; Uehara Y; Saita M; Inui A; Isonuma H; Naito T
    Jpn J Infect Dis; 2016; 69(1):33-8. PubMed ID: 25971320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
    Troya J; Montejano R; Ryan P; Gómez C; Matarranz M; Cabello A; Vera F; Sepúlveda MA; Santos I; Samperiz G; Bachiller P; Boix V; Barrufet P; Cervero M; Sanz J; Solís J; Yllescas M; Valencia E;
    PLoS One; 2018; 13(6):e0198768. PubMed ID: 29902204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
    Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
    AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
    Ferrer E; Niubo J; Crespo M; Gatell JM; Sanz J; Veloso S; Llibre JM; Barrufet P; Sanchez P; Podzamczer D;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):253-5. PubMed ID: 17895768
    [No Abstract]   [Full Text] [Related]  

  • 10. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
    Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir, abacavir and lamivudine as HIV therapy.
    Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
    Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
    Galli L; Poli A; Muccini C; Galizzi N; Danise A; Spagnuolo V; Gianotti N; Carini E; Lazzarin A; Castagna A
    Infect Dis (Lond); 2018 Mar; 50(3):220-222. PubMed ID: 28891371
    [No Abstract]   [Full Text] [Related]  

  • 13. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
    Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
    PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
    Lim ZC; Hoo GS; Ang JH; Teng CB; Ang LW; Lee CC; Leo YS; Law HL; Ng OT; Wong CS
    AIDS Res Ther; 2021 Nov; 18(1):80. PubMed ID: 34724931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM; Schriever CA; Badowski ME
    Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.